| abstract |
In some embodiments, therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer, wherein the cancer is an ARIDl A-mutated cancer. In some embodiments, the therapeutic treatments disclosed include methods of treating ARIDlA-mutated cancer in a subject comprising the step of administering a therapeutically effective dose of a histone deacetylase 6 (HDAC6) inhibitor to the subject, including a human subject. In some embodiments, the HDAC6 inhibitors are administered in conjunction with a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor. |